• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Regulatory

FDA approves QNASL for children

Accoding to Teva, the FDA has approved the company's QNASL beclomethasone dipropionate HFA nasal spray for the treatment of allergic rhinitis symptoms in children aged 4-11. The supplemental NDA for the pediatric product was accepted by the FDA in May 2013. The children's version of QNASL is a 40 µg formulation; the adult version, which was approved in 2012, is an … [Read more...] about FDA approves QNASL for children

Insmed provides update on its pipeline

According to Insmed, the company has filed an MAA for its Arikayce liposomal amikacin for inhalation, and it has been informed by the EMA that the only remaining issue, a review of the Pediatric Investigation Plan (PIP) by the agency's Pediatric Committee, should be finished by the first quarter of 2015. A trial of Arikayce for the treatment of resistant … [Read more...] about Insmed provides update on its pipeline

Hovione announces results of FDA pre-approval inspection

Hovione has announced that the FDA has found its Loures, Portugal manufacturing site to be GMP compliant, although the agency issued a Form 483 citing three inspectional observations. The inspection took place from December 1 to December 5, 2014. In October 2013, the company announced that it had completed a successful FDA inspection of the Loures facility with no … [Read more...] about Hovione announces results of FDA pre-approval inspection

FDA approves PulmoFlow’s Kitabis Pak for CF

PulmoFlow has announced that the FDA has approved its NDA for Kitabis Pak, generic tobramycin inhalation solution packaged with a PARI LC PLUS nebulizer, for the treatment P. aeruginosa infections in cystic fibrosis patients. PARI Respiratory Equipment will distribute the product, which will be priced similarly to generic tobramycin alone, the company said. In … [Read more...] about FDA approves PulmoFlow’s Kitabis Pak for CF

Meda and Cipla sue Apotex over Dymista patents

Meda Pharmaceuticals and Cipla have filed suit against Apotex in the Delaware Federal District Court, claiming that Apotex's submission of an ANDA for a generic version of Dymista azelastine HCl/fluticasone propionate nasal spray violates patents related to Dymista that will not expire until 2026. Meda holds the licenses to US patents 8,163,723 and 8,168,620 … [Read more...] about Meda and Cipla sue Apotex over Dymista patents

Avanir gets Complete Response Letter for intranasal sumatriptan

According to Avanir Pharmaceuticals, it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for AVP-825 intranasal sumatriptan for the treatment of migraine. The company had recently warned that its NDA was unlikely to be approved by the PDUFA date due to FDA concerns about human factors issues. In the CRL, "the FDA … [Read more...] about Avanir gets Complete Response Letter for intranasal sumatriptan

QIDP designation for two Bayer inhaled antibiotics

According to Bayer, its Amikacin Inhale inhalation solution and its ciprofloxacin DPI have both been granted qualified infectious disease product (QIDP) designation by the FDA. Both products are currently in Phase 3 development. Bayer HealthCare Pharmaceuticals VP and Head Dario Mirski commented, "We welcome the QIDP designation for Ciprofloxacin DPI and Amikacin … [Read more...] about QIDP designation for two Bayer inhaled antibiotics

Duaklir Genuair gets European marketing authorization

According to AstraZeneca, the European Commission has approved the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of the product in September 2014, and AstraZeneca acquired the rights to commercialize the inhaler in the EU when it acquired … [Read more...] about Duaklir Genuair gets European marketing authorization

Two more approvals for AirFluSal Forspiro

According to Sandoz, Ireland and the Czech Republic have approved marketing applications for the AirFluSal Forspiro salmeterol/fluticasone DPI in 50-250 and 50-500 µg dosage forms for the treatment of asthma and/or COPD. The Czech approval triggers a €1.5 million milestone payment from Sandoz to Vectura. Sandoz Head of Global Respiratory Jan-Torsten Tews said, “We … [Read more...] about Two more approvals for AirFluSal Forspiro

Avanir says NDA for AVP-825 unlikely to be approved by PDUFA date

According to Avanir Pharmaceuticals,the FDA has issued a Discipline Review letter in response to the company's NDA for AVP-825 intranasal dry powder sumatriptan requesting that the company "optimize the product-user interface" and conduct additional human factor testing. AVP-825 is delivered using OptiNose's Breath Powdered intranasal delivery device. Although the … [Read more...] about Avanir says NDA for AVP-825 unlikely to be approved by PDUFA date

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 68
  • Page 69
  • Page 70
  • Page 71
  • Page 72
  • Interim pages omitted …
  • Page 99
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews